Neutrophil activation by plasma opsonized polymeric microspheres: inhibitory effect of pluronic F127.
The phagocytosis of drug-loaded polymeric microspheres by white blood cells, such as neutrophils or mononuclear cells, represents the major clearance mechanism by which this foreign material is eliminated from the body. The process of phagocytosis requires the activation of the white blood cells by the microsphere surface, followed by binding and engulfment. Phagocytosis may result in the removal of the microspheres from the blood or the disease site and an inflammatory response. Therefore, we have studied the level of neutrophil activation by microspheres ( +/- opsonization) manufactured from various biomaterials or polymers. Polymer microspheres with equivalent size distributions were made from poly (DL-lactic acid) (PLA), poly(epsilon-caprolactone) (PCL), poly(methyl methacrylate) (PMMA) or a 50 : 50 blend of PLA: poly(ethylene-co-vinyl acetate) (PLA: EVA). Neutrophils were isolated from human blood and activation of these cells by microspheres was measured by chemiluminescence (CL). All four types of microspheres induced only low levels of CL, however these levels were enhanced significantly if the microspheres were pretreated with plasma or IgG suggesting an opsonization effect. The adsorption of IgG or proteins from plasma was confirmed by polyacrylamide gel electrophoresis (SDS-PAGE). The poloxamer Pluronic F127 inhibited the opsonization effect of IgG and plasma on all four types of microspheres and inhibited protein adsorption as measured by SDS-PAGE. Since neutrophil activation is part of the inflammation process in vivo, these in vitro data suggest that all four types of microspheres are likely to be inflammatory if injected into body compartments containing plasma-derived fluids. Pretreatment of the microspheres with Pluronic F127 may reduce the inflammatory potential of the microspheres.
Jackson
J K
JK
Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.
Springate
C M
CM
Hunter
W L
WL
Burt
H M
HM
D001672:Biocompatible Materials; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D019344:Lactic Acid; D008863:Microspheres; D018375:Neutrophil Activation / Q000187:drug effects* / Q000502:physiology; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology*; D010587:Phagocytosis / Q000187:drug effects / Q000502:physiology*; D020442:Poloxamer / Q000494:pharmacology*; D011091:Polyesters; D011108:Polymers; D019904:Polymethyl Methacrylate; D013481:Superoxides / Q000097:blood; D013501:Surface-Active Agents / Q000494:pharmacology
D001672:Biocompatible Materials; D011091:Polyesters; D011108:Polymers; D013501:Surface-Active Agents; D020442:Poloxamer; D013481:Superoxides; C016240:polycaprolactone; D019344:Lactic Acid; C033616:poly(lactide); D019904:Polymethyl Methacrylate